Results 141 to 150 of about 20,527 (318)

Higher prevalence of dupilumab‐induced ocular adverse events in atopic dermatitis compared to asthma: A daily practice analysis

Clinical and Translational Allergy
Background Dupilumab has been shown to be an effective treatment in moderate‐to‐severe atopic dermatitis (AD) and severe asthma (SA). However, comparative real‐world analyses of adverse events (AE), particularly dupilumab‐associated ocular surface ...
Anne R. Schlösser, Lotte Bult, John C. Thelen, Alberta A. H. J. Thiadens, Renske Schappin, Tamar E. C. Nijsten, Johannes C. C. M. in 't Veen, Gerrit J. Braunstahl, DirkJan Hijnen   +8 more
doaj   +1 more source

Dupilumab-induced erythema nodosum [PDF]

JAAD Case Reports, 2022
Benjamin K. Stoff, Ron J. Feldman, Danielle E. Mustin, Travis W. Blalock, Emily F. Cole, Merin E. Kalangara   +5 more
openaire   +4 more sources

Expression of IL‐4 Receptor Alpha in Ectopic Lymphoid Tissue in Chronic Rhinosinusitis

Allergy, EarlyView.
Kengo Kanai, Hiroyuki Kusano, Aiko Oka, Marie Yamada, Ryo Takagi, Isao Suzaki, Kojiro Hirano, Junqin Bai, Takayuki Shiomi, Mitsuhiro Okano   +9 more
wiley   +1 more source

Biologic Prescription Patterns and Biomarker Determinants of First‐Line Dupilumab in Danish Adult Patients With Severe Asthma and Comorbid Atopic Dermatitis

Clinical &Experimental Allergy, EarlyView.
Almost one in five patients receiving biological treatment for severe asthma has comorbid atopic dermatitis. Patients with comorbid atopic dermatitis represent a distinct phenotype with early‐onset, allergic asthma. Comorbid atopic dermatitis impacts the choice of biologic for severe asthma in real‐life practice. IgE, immunoglobulin E; FeNO, fractional
Marianne Baastrup Soendergaard, Kjell Erik Julius Håkansson, Susanne Hansen, Anne‐Sofie Bjerrum, Johannes Martin Schmid, Sofie Lock Johansson, Linda Makowska Rasmussen, Barbara Bonnesen, Roxana Vijdea, Anna von Bülow, Niels Steen Krogh, Ole Hilberg, Simon Francis Thomsen, Charlotte Suppli Ulrik, Celeste Porsbjerg   +14 more
wiley   +1 more source

Persistent Eosinophilic Inflammation Is Not a Feature of Type 2 CRS Patients Failing Anti‐IL‐5R Therapy and Requiring Class Switching to Anti‐IL‐4/13 [PDF]

Background: Type 2 inflammation dominates eosinophilic chronic rhinosinusitis (eCRS) and adult onset asthma. IL-4, -5, and -13 are prominent disease mediators. Disease control can be achieved with biologic therapies.
Campbell, Raewyn G, Choy, Christine, Earls, Peter, Harvey, Richard J, hiel, Cedric, Kalish, Larry, Meerwein, Christian M, Sacks, Peta‐Lee, Sacks, Raymond   +8 more
core   +1 more source

Efficacy of Omalizumab, Dupilumab, and Remibrutinib in Chronic Spontaneous Urticaria: Phase Data and Placebo Response

Allergy, EarlyView.
Murat Türk, İnsu Yılmaz, Ragıp Ertaş, Emek Kocatürk   +3 more
wiley   +1 more source

International survey of treatment practices for atopic dermatitis in pregnant and breastfeeding women: Physician perspectives

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives Systemic treatment of pregnant/breastfeeding atopic dermatitis (AD) patients is challenging due to limited safety data. We explored treatment practices with systemic agents, including the guideline‐recommended cyclosporine as the first systemic choice as well as emerging therapies, in this vulnerable population ...
Manuel P. Pereira, Katarina Stevanovic, Emek Kocatürk, Cathrin Meesch, Ingrid van Hofman, Prema S. Vaswani, Jonathan A. Bernstein, Dayanne Bruscky, Herberto J. Chong‐Neto, Chia‐Yu Chu, Roberta Fachini Jardim Criado, Luis Felipe Ensina, Ana M. Giménez‐Arnau, Kiran Godse, Maia Gotua, Stamatios Gregoriou, Kanokvalai Kulthanan, Charlotte G. Mortz, Natasa Teovska Mitrevska, Esen Özkaya, Prajwal Pudasaini, Mara Morelo Rocha Felix, Catalina Rincón Pérez, Claudio Alberto Salvador Parisi, Gonzalo N. Ramón, Efstratios Vakirlis, Zuotao Zhao, Lisa A. Beck, Marjolein de Bruin‐Weller, Michael Cork, Norito Katoh, Thomas Werfel, Margitta Worm, Andreas Wollenberg, Torsten Zuberbier   +34 more
wiley   +1 more source

Relationship Between Bronchodilator Reversibility and Spirometry Response to Dupilumab in Type 2 High Uncontrolled Severe Asthma

Clinical &Experimental Allergy, Volume 55, Issue 3, Page 253-255, March 2025.
Robert Greig, Kirsten Stewart, Chris RuiWen Kuo, Rory Chan, Brian Lipworth   +4 more
wiley   +1 more source

A phase IIb single‐center study to assess the efficacy of apremilast for the treatment of nummular eczema

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background The pathogenesis of nummular eczema (NE) remains unclear, and no targeted therapy has been approved. Apremilast is a small molecule inhibitor targeting phosphodiesterase‐4. Patients and Methods A phase IIb randomized, double‐blind, placebo‐controlled study evaluating the effects of apremilast or placebo in patients with NE.
Alexander Böhner, Peter Seiringer, Viktoria Kleeberger, Danielle Rogner, Christian Oesterlin, Tilo Biedermann, Kilian Eyerich, Felix Lauffer   +7 more
wiley   +1 more source

282 Risk of skin infections with dupilumab for atopic dermatitis: Systematic review and meta-analysis of randomized controlled trials

, 2017
Aaron M. Drucker, Patrick Fleming
openalex   +1 more source